CRISPR/Cas technology as a promising weapon to combat viral infections.
Autor: | Escalona-Noguero C; Fundación IMDEA-Nanociencia, Madrid, Spain., López-Valls M; Fundación IMDEA-Nanociencia, Madrid, Spain., Sot B; Fundación IMDEA-Nanociencia, Madrid, Spain.; Nanobiotecnología (IMDEA-Nanociencia), Unidad Asociada al Centro Nacional de Biotecnología (CSIC), Madrid, Spain. |
---|---|
Jazyk: | angličtina |
Zdroj: | BioEssays : news and reviews in molecular, cellular and developmental biology [Bioessays] 2021 Apr; Vol. 43 (4), pp. e2000315. Date of Electronic Publication: 2021 Feb 11. |
DOI: | 10.1002/bies.202000315 |
Abstrakt: | The versatile clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system has emerged as a promising technology for therapy and molecular diagnosis. It is especially suited for overcoming viral infections outbreaks, since their effective control relies on an efficient treatment, but also on a fast diagnosis to prevent disease dissemination. The CRISPR toolbox offers DNA- and RNA-targeting nucleases that constitute dual weapons against viruses. They allow both the manipulation of viral and host genomes for therapeutic purposes and the detection of viral nucleic acids in "Point of Care" sensor devices. Here, we thoroughly review recent advances in the use of the CRISPR/Cas system for the treatment and diagnosis of viral deleterious infections such as HIV or SARS-CoV-2, examining their strengths and limitations. We describe the main points to consider when designing CRISPR antiviral strategies and the scientific efforts to develop more sensitive CRISPR-based viral detectors. Finally, we discuss future prospects to improve both applications. Also see the video abstract here: https://www.youtube.com/watch?v=C0z1dLpJWl4. (© 2021 Wiley Periodicals LLC.) |
Databáze: | MEDLINE |
Externí odkaz: |